Amarin Corp Plc (AMRN)

[dogn]

Epadel EM - From Mochida annual report

Epadel, launched in 1990, was the world’s first preparation of high purity eicosapentaenoic acid (EPA). EPA is one of the fatty acids found in fish such as sardines. Furthermore, we improved the formulation of this product aiming at maximizing intestinal absorption and launched Epadel EM in 2022.

“Looking at our development pipelines, we obtained manufacturing and marketing approval for Epadel EM (development code: MND-2119), for the treatment of hyperlipidemia.”

2022 Epadel EM
(a self-emulsifying formulation of highly purified EPA)

“We are also leveraging our alliances to globally expand our EPA drug with high purity in China, Thailand, Vietnam and the United States. In Thailand, the subsidiary of Meiji Seika Pharma Co., Ltd. obtained approval to import and market our EPA drug for the treatment of hypertriglyceridemia in October 2020 and commenced sales in April 2021. In Vietnam, an alliance partner of Meiji Seika Pharma is in the process of applying for approval to import and market our EPA drug.”
p. 13: In addition, we will strive to leverage our experience as a leading manufacturer of highly purified EPA drug in marketing activities for Epadel EM, a self-emulsifying
formulation of highly purified EPA launched in September 2022.

“Cardiovascular medicine
Urece®, a selective urate reabsorption inhibitor (SURI) released in 2020, is a therapeutic agent for gout and hyperuricemia. …
We are also making our presence felt in the cardiovascular field as a leading manufacturer of highly purified EPA drugs. In addition to Epadel, a high-purity EPA drug, which, through various mechanisms, slows atherosclerotic plaque progression, we launched Epadel EM, a new self-emulsifying formulation of Epadel, in September 2022. Epadel EM is a new formulation of Epadel for the treatment of hyperlipidemia. It uses self-emulsifying formulation technology in order to improve gastrointestinal absorption. As the world’s first high-purity EPA drug that can be given in a single daily dose, we expect Epadel EM to be able to help improve the QOL of patients.
With these high-purity EPA drugs and other products such as Atelec®, a calcium channel blocker with a long-acting hypotensive effect, and Treprost®, a therapeutic product for pulmonary arterial hypertension, we are taking on the cardiovascular field.
From https://www.mochida.co.jp/english/annual/docs/ir2022e_p.pdf

Why no mention of licenses or alliance with Amarin?
When Vascepa EM?